Tag Archives: healthcare

Novo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs

Novo Holdings
  • Financing to support the development of Orbis’ pipeline of next-generation macrocycles, nCycles, with an initial focus on validated blockbuster biologic targets
  • Orbis’ nGen platform systematically explores oral macrocycle design with automated chemistry and machine learning
  • Novo Holdings Partner, Morten Graugaard, to lead Orbis as CEO

COPENHAGEN – January 6, 2025 – Novo Holdings today announced its participation in a €90 million Series A financing for Orbis Medicines. The round was led by New Enterprise Associates (NEA), with participation from new investors including Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark, alongside existing investors Novo Holdings and Forbion. Morten Graugaard, Partner at Novo Holdings, has been appointed the Chief Executive Officer of Orbis Medicines following nearly three years serving as Executive Chair of its Board of Directors.

Orbis was founded in 2021 by the Seed Investments team of Novo Holdings to pioneer a new era for oral macrocycle drug discovery and build on the ground-breaking science developed by Professor Christian Heinis and Sevan Habeshian at the Swiss Federal Institute of Technology in Lausanne (EPFL). João Ribas, Principal, Novo Holdings, and Morten Graugaard provided highly collaborative operational management and strategic guidance, exemplifying the team’s active, hands-on approach to venture creation.

Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties. However, developing these compounds as oral drugs has historically been a significant challenge. Orbis is focused on using its leading nGen platform to generate high-value oral alternatives to blockbuster biologic drugs and targets to maximize value for patients.

“The benefits of an oral format include dose control, convenience, ease of dosing, and feasibility for much larger populations of patients. Orbis is leveraging macrocycles to unlock these benefits in major areas validated by existing biologics, and we are proud to have played an integral role in shaping the company from its earliest stages,” said João Ribas, Principal, Novo Holdings. “The combination of automated chemical synthesis, high-throughput assays, and machine learning ignited our enthusiasm and drove us to start collaborating to build Orbis before its first financing round. We congratulate Morten on his appointment and the team on their successes to-date and look forward to advancing the future of macrocycles.”

About Orbis Medicines
Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its nGen platform systematically delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis’ pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection. In 2024, Orbis raised a EUR 26 million series seed round co-led by Novo Holdings and Forbion. Proof-of-concept of Orbis’ work has been published in Nature Communications and Nature Chemical Biology. The company is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: www.orbismedicines.com.

About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk

Further information

Christian Mostrup
Head of Public Relations
+ 45 306 74805
cims@novo.dk

Categories: News

Tags:

Hologic Completes Acquisition of Gynesonics, Inc

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million.

“We are excited to complete the acquisition of Gynesonics and to increase access to their Sonata® System, which complements and expands our range of minimally invasive solutions for heavy periods and fibroids,” said Brandon Schnittker, President of Surgical Solutions at Hologic. “As global champions for women’s health, we are dedicated to empowering surgeons with diverse, cutting-edge treatment options as we strive to transform women’s lives for the better.”

The Sonata System is a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The technology combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.

“As we embark on this new phase with Hologic, we are excited to see the continued success of the Sonata System, which has already made a difference in the lives of thousands of women,” said Skip Baldino, President and Chief Executive Officer of Gynesonics. “Hologic’s commitment to women’s health and their leadership in innovation make them a perfect fit for our organization.”

About Hologic

Hologic, Inc. is a global leader in women’s health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com and connect with us on LinkedIn, Facebook, X (Twitter), Instagram and YouTube.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; strategies, positioning, resources, capabilities and expectations for future performance; and financial outlook and other guidance. These forward-looking statements are based upon assumptions made as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the possibility that the anticipated benefits from the transaction or products cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Gynesonics’ operations with those of Hologic will be greater than expected; the coverage and reimbursement decisions of third-party payers and the guidelines, recommendations, and studies published by various organizations relating to the use of products and treatments; the ability to successfully manage ongoing organizational and strategic changes, including Hologic’s ability to attract, motivate and retain key employees; the development of new competitive technologies and products; regulatory approvals and clearances for products; the anticipated development of markets in which products are sold into and the success of products in these markets; the anticipated performance and benefits of products; estimated asset and liability values; anticipated trends relating to Hologic’s financial condition or results of operations; and Hologic’s capital resources and the adequacy thereof.

The risks included above are not exhaustive. Other factors that could adversely affect Hologic’s business and prospects are described in Hologic’s filings with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, The Science of Sure, Gynesonics and Sonata are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Source: Hologic, Inc.

Media Contact
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com

Investor Contact
Michael Watts
Corporate Vice President, Investor Relations
(+1) 858.410.8514
michael.watts@hologic.com
Source: Hologic, Inc.

Categories: News

Tags:

Remodel Health Raises More Than $100 Million to Continue Expansion in ICHRA Market

Oak HC FT

Remodel Health, the #1 Individual Coverage Health Reimbursement Arrangement (ICHRA) provider for brokers, today announced it has raised more than $100 million from Oak HC/FT and Hercules Capital, Inc. (NYSE: HTGC) in growth funding.

Remodel offers an end-to-end, white-labeled tech platform that supports employers and employees with everything they need tolaunch and access their ICHRA plans, including plan creation andadministration, call center support, automated quoting, employee onboarding, HRIS integrations and payments with carriers and access to ancillary products. Starting with the group to individual health insurance shift in 2015, Remodel has become a dominant player in the ICHRA space, bolstered by the acquisition of PeopleKeep in early 2024. Together, the two companies are uniquely positioned to serve small, medium and large employers, with a suite of products across ICHRA and QSEHRA. With this investment from Oak HC/FT and Hercules Capital, Remodel will look to continue its national expansion.

Remodel stands apart from the competitive set with its meaningful scale and a go-to-market motion defined by its white-glove service, deep broker relationships and easy-to-understand approach to marketing and sales. Importantly, as employer health insurance premiums continue to increase, ICHRA provides Remodel’s customers with predictable annual benefits costs, driving stability and an average of 30% savings for the office of the CFO. Over the past 12 months, Remodel has focused more on partnering with insurance brokers and agencies tosupport its ICHRA expansion across the U.S. As a result, the Remodel business grew 11x YoY in broker-led ICHRA bookings and this will be a key area of growthand expansion for the business moving forward.

“We are on a mission to resource organizations with missions that matter, partnering with employers and their brokers to do so. Remodel Co-Founders Justin Clements and Scott Lingle and I started trailblazingin 2015, and PeopleKeep founder Paul Zane Pilzer identified this shift likepension to 401(k) in the early 2000’s,” said Austin Lehman, CEO of Remodel Health. “We are now seeing it begin to come to fruition. The Oak team have been great dreamers with us and have great connections in the insurance payer space to accelerate growth and help increase access to medical care and resource organizations with missions that matter.”

ICHRA was created in 2020 as a flexible alternative to traditional group health insurance, offering choices around contribution levels to employers and more personalized options around benefits for employees. Similar to a 401K, employers of any size can provide an allowance of pre-taxdollars to their employees. This is used by employees for the purchase of someor all of their healthcare premiums for insurance bought on the ACA exchanges. It offers an exciting cost-savings proposition for employers, particularly small and mid-size ones, who want to offer health insurance to their teams, by allowing them to move their employees to state risk pools to help offset costs, instead of trying to level-fund or self-insure.

“We have been looking at the ICHRA space for a few years now, waiting for a stand out company with the combination of hyper-scaling potential, an ambitious go-to-market strategy and focused dedication from the leadership team,” said Andrew Adams, Co-Founder and Managing Partner, Oak HC/FT. “We are honored that the Remodel team chose to partner with us and cannot wait to support them in their efforts to build out the ICHRA market for employers and brokers across the U.S.”

Since its launch, the ICHRA market has been steadily increasing and is projected to 10X by 2032.According to the HRA Council, ICHRAadoption increased 29% from 2023 to 2024, with Applicable Large Employersgrowing at the highest rate – of 84%. Remodel’s approach to distribution and plan partnership best positions them to take advantage of this growth, now and in the future.

About Remodel Health

Remodel Health isthe expert guide for employers and brokers navigating the complexities oftransitioning to ICHRA. With nearly a decade of experience in the individualhealth benefits space, our proprietary software and licensed health benefits experts deliver tailored solutions for businesses with 100 to 10,000 employees. Committed to best-in-class customer service, we provide hands-on support throughout the process, ensuring successful implementation and long-term success. Learn more about how we transform health benefits at remodelhealth.com.

About PeopleKeep

PeopleKeep specializes in helping small and midsize businesses offer affordable, flexible health benefits through the ICHRA and qualified small employer HRA (QSEHRA). By focusing on expanding access to coverage for employees often overlooked by traditional employer-sponsored plans due to cost and complexity, PeopleKeep empowers small employers to thrive. With easy-to-use software, automated compliance, and a seamless employee experience, PeopleKeep is committed tosimplifying benefits administration and making health coverage more accessible.

About Oak HC/FT

Oak HC/FT is a venture and growth equity firmspecializing in investments in fintech and healthcare. Using partnership as afoundation, Oak HC/FT guides companies and founders at every stage, from seedto growth, to create businesses that make a measurable and lasting impact.Founded in 2014, Oak HC/FT has invested in over 85 portfolio companies and hasover $5.3 billion in assets under management. Oak HC/FT is headquartered inStamford, CT, with an office in San Francisco, CA. Follow Oak HC/FT on LinkedIn and X and learn more at https://www.oakhcft.com/.

About Hercules Capital, Inc.

Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venturegrowth loans to high-growth, innovative venture capital-backed companies in abroad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $21 billion to over 660companies and is the lender of choice for entrepreneurs and venture capitalfirms seeking growth capital financing. Companies interested in learning moreabout financing opportunities should contact info@htgc.com.

Categories: News

Tags:

Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners

IK Partners

Paris, 19 December 2024

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible) and EB Development announce the final outcome of the takeover bid initiated by EB Development (the “Offer“), based on the results published on 18 December by the Autorité des marchés financiers (AMF) at the end of the reopening period of the Offer (the “Reopened Offer“).

644,911 ordinary shares were tendered to the Reopened Offer, which closed on 17 December 2024. These are in addition to the 4,582,971 ordinary shares tendered to the Initial Offer, giving a total of 5,227,882 ordinary shares tendered to the Offer, enabling EB Development, acting in conjunction with funds managed by NextStage AM and IK Partners, and Mr. Denis Fortier, Chairman and CEO, and other members of the Board of Directors and senior management of the Company ,[1] to hold, after assimilation of the treasury shares held by Eurobio Scientific (the “Company“), 9,113,592 shares representing 88.92% of the share capital and voting rights of the Company.

As the percentage of share capital and voting rights attained following the Reopened Offer is below the 90% threshold allowing the implementation of a squeeze-out procedure, the additional price of €1.25 per share will not be paid. Settlement and delivery will take place on 23 December 2024.

Denis Fortier, Chairman and CEO of Eurobio Scientific, said: “The results of the takeover bid give Eurobio Scientific the means to accelerate its development with the support of NextStage and now IK Partners, active shareholders who share our strategy and have a good knowledge of our in vitro diagnostics and intelligent health markets. We would like to thank our shareholders for their confidence and support in making this transaction a success.”

NextStage AM acquired a stake in Eurobio Scientific on 18 May 2022 through the creation of a joint holding company with the entrepreneurs called “EurobioNext”. NextStage AM invested in the company through the “Pépites et Territoires” programme by AXA France & NextStage AM and its NextStage EverGreen vehicle.  NextStage AM has supported Eurobio Scientific in structuring its management team and accelerating its external growth strategy, in particular, through significant M&A transactions (including the acquisition of the Dutch company GenDx, one of the world leaders in HLA typing for transplant compatibility, in August 2022).[2]

NextStage AM and IK Partners, as core shareholders, will continue to support the group’s team of entrepreneurs in this new stage of the Company’s growth.

Grégoire Sentilhes, Chairman and co-founder of NextStage AM, commented: “Since May 2022, the team of entrepreneurs led by Denis Fortier has accelerated the transformation of the group post-Covid, in particular through the acquisition of GenDx, by strengthening the part of its business dedicated to proprietary products. We are delighted to be pursuing the development of Eurobio Scientific, which has the potential to become a leading SME in its market, alongside IK Partners, a leading investor who shares our vision and entrepreneurial values.”

Rémi Buttiaux, Managing Partner at IK Partners, added: “Eurobio Scientific has established itself as a market leader in the field of in vitro diagnostics and we are looking forward to working closely with the management team, NextStage AM and other stakeholders to support this next phase of development for the business.”

Warning:

This press release has been prepared for information purposes only. It does not constitute an offer to purchase or exchange or the solicitation of an offer to sell or exchange any securities of Eurobio Scientific S.A. or an offer to purchase or exchange or the solicitation of an offer to sell or exchange any securities of Eurobio Scientific S.A. The release, publication or distribution of this press release may be restricted by law in certain jurisdictions and, accordingly, persons in possession of this press release in such jurisdictions should inform themselves of and observe any applicable legal restrictions. Investors and shareholders in France are strongly advised to read the Offer documents referred to in this announcement as they contain important information about the proposed transaction and other related matters. EB Development’s offer document and “other information” document are available on the websites of the AMF (www.amf-france.org) and Eurobio Scientific S.A. (www.eurobio-scientific.com) and may be obtained free of charge on request from EB Development (43, avenue de Friedland, 75008 Paris, Crédit Industriel et Commercial (6, avenue de Provence, 75009 Paris) and Degroof Petercam Wealth Management (44, rue de Lisbonne, 75008 Paris). Eurobio Scientific’s note in response and “other information” document are available on the AMF (www.amf-france.org) and Eurobio Scientific S.A. (www.eurobio-scientific.com) websites and may be obtained free of charge on request from Eurobio Scientific S.A. (7, avenue de Scandinavie, ZA de Courtaboeuf, 91953 Les Ulis). Neither Eurobio Scientific S.A., EB Development, nor their respective shareholders, advisers or representatives accept any liability whatsoever in connection with the use by any person of this press release or its contents, or more generally in connection with this press release.

[1] Denis Fortier (Chairman and Chief Executive Officer), Cathie Marsais (Chief Operating Officer), Olivier Bosc (Chief Operating Officer), Jean-Michel Carle-Grandmougin (Chief Operating Officer and member of the Board of Directors) and Hervé Duchesne de Lamotte (member of the Board of Directors).

[2] https://nextstage-am.com/eurobio-scientific-participation-de-nextstage-am-annonce-la-signature-dun-accord-en-vue-dacquerir-gendx-leader-mondial-du-diagnostic-hla-aux-pays-bas/

For further questions, please contact:

Eurobio Scientific Group
Denis Fortier, Chairman and CEO
Olivier Bosc, Managing Director / CFO
Tel. +33 1 69 79 64 80

Calyptus
Mathieu Calleux
Investor Relations
Tel. +33 1 53 65 68 68
eurobio-scientific@calyptus.net

NextStage AM
Ghita Farage – gf@nextstage.com – +33 6 10 50 32 56

Shan
Laurence Tovi – laurence.tovi@shan.fr – +33 6 20 58 29 02 / Lola Gozlan – lola.gozlan@shan.fr – +33 6 24 76 83 40 / Clara Flore – clara.flore@shan.fr – +33 6 16 04 64 33

IK Partners
Vidya Verlkumar – vidya.verlkumar@ikpartners.com – +44 (0) 7787 558 193

About Eurobio Scientific

Eurobio Scientific is a major player in the field of speciality in vitro diagnostics. It is involved in the research and marketing of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and offers dedicated reagents to research laboratories, including pharmaceutical and biotechnology companies. With its many partnerships and strong hospital presence, Eurobio Scientific has its own extensive distribution network and a portfolio of proprietary products. The Group has around 320 employees, four production units based in the Paris region, Germany, the Netherlands and the United States, and subsidiaries in Milan (Italy), Dorking (UK), Sissach (Switzerland), Bünde (Germany), Antwerp (Belgium) and Utrecht (Netherlands).

For more information, visit www.eurobio-scientific.com

Eurobio Scientific shares are listed on Euronext Growth Paris.
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.mnemonic: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

Read More

About EB Development

EB Development is the initiator of the Offer and intends to bring together in its capital, directly or indirectly, funds managed by IK Partners and Eurobio Scientific’s reference shareholders, including Nextstage and the Company’s managers and directors.

Read More

About NextStage AM

NextStage AM is an independent asset management company based in Paris and approved by the AMF. Since its inception in 2002, NextStage AM has cultivated an “entrepreneur-investor” philosophy and is one of the pioneers and specialists in innovative and patient growth capital in France. NextStage AM has developed, step by step, a multi-strategy private equity platform which, in terms of assets under management and advised, represents more than €8.7 billion as at 30 September 2024, both directly and indirectly. NextStage AM invests in a limited number of French and European innovative and growth SMEs and ETIs (81 companies in the portfolio on 30/09/2024), to which it provides entrepreneurial investor expertise and strong operational support to ensure their successful transformation. NextStage AM provides long-term support to SMEs and SMIs involved in intelligent healthcare, environmental and energy innovation and digital transformation. It provides them with the means to accelerate their development and their capacity for innovation in order to become the “Champions” of their markets, both in France and internationally, through organic and/or external growth. For more information, visit nextstage-am.com

Read More

About IK Partners

IK Partners (“IK”) is a European private equity firm focusing on investments in the Benelux, DACH, France, the Nordic countries and the UK. Since 1989, IK has raised over €17 billion of capital and invested in more than 195 European companies. IK supports companies with strong underlying potential, working in partnership with management teams and investors to create strong, well-positioned businesses with excellent long-term prospects. For more information, visit ikpartners.com

Read More

Categories: News

Tags:

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

GIlde Healthcare
December 12, 2024
Barcelona (Spain)
  • SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations
  • Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored natural history study in Stargardt disease
  • First ever IND clearance for a Protein Splicing gene therapy

SpliceBio, a genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that the U.S. Food & Drug Administration (FDA) has cleared its investigational new drug (IND) application for lead program SB-007. SB-007 is the only clinical-stage therapeutic addressing the root genetic cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations.

Miquel Vila-Perelló, Ph.D., Chief Executive Officer, and Co-Founder of SpliceBio, said: “The FDA IND clearance of SB-007 is a significant achievement for SpliceBio and Stargardt disease patients. As the first-ever IND for a Protein Splicing gene therapy, it is a huge step forward to demonstrate the potential of this new therapeutic modality to address diseases caused by mutations in large genes such as ABCA4. SB-007 is an adeno-associated viral (AAV) vector gene therapy aimed at restoring expression of the full-length ABCA4 protein, and the only clinical-stage therapy with the potential to help all Stargardt patients. We look forward to accelerating the clinical development of SB-007, building on the Orphan Drug Designation granted by the FDA in 2024, and advancing this potentially life-changing therapeutic for patients with Stargardt disease.”

“Stargardt disease has been a challenge for the development of gene therapies due to the large size of the ABCA4 gene, and currently has no approved therapies available,” said Professor Paul Yang, M.D., Ph.D., Chief of the Paul H. Casey Ophthalmic Genetics Division at Casey Eye Institute at Oregon Health & Science University. “This new therapy utilizes a unique approach to replace the full-size, normal ABCA4 protein at high efficiency, which addresses the root cause of Stargardt disease across any pathogenic variant in the ABCA4 gene. This IND clearance represents a major milestone in the field and I am thrilled to be part of the clinical studies exploring this promising approach that could transform the lives of Stargardt disease patients.”

SpliceBio plans to initiate enrolment in the Phase 1/2 ASTRA study in the first half of 2025. ASTRA will evaluate the safety and efficacy of a single dose of SB-007 administered subretinally in patients with Stargardt disease. In March 2024, SpliceBio launched the POLARIS trial, a pioneering company-sponsored natural history study of Stargardt disease designed to evaluate disease progression, refine endpoints, and streamline eligibility criteria for accelerated enrolment into the Phase 1/2 ASTRA study. This study will enable Stargardt disease patients to benefit from more precise diagnoses, more rigorous disease monitoring, and potentially faster access to innovative therapies.

The SpliceBio Management team will be attending J.P. Morgan’s 43rd Annual Healthcare Conference 2025, being held in San Francisco from 13-16 January 2025. Please get in contact to schedule a meeting at bd@splice.bio.

About Stargardt disease
Stargardt disease is the most common form of inherited juvenile macular degeneration, affecting approximately 1 in 8,000 to 10,000 individuals. Caused by mutations in the ABCA4 gene, Stargardt disease leads to the progressive loss of central vision due to damage to the central region of the retina known as the macula. The disease is variable in the age of onset, including early onset in children and adolescents and late-onset forms in adulthood. There are no approved treatments, and patients face significant challenges in daily life as the disease progresses. Stargardt disease has remained elusive to genetic medicines due to the large size of the ABCA4 gene.

About SB-007
SB-007 is a Protein Splicing dual AAV gene therapy that delivers the full-length ABCA4 gene and aims to restore expression of the native ABCA4 protein in the retina. It has demonstrated robust pharmacological activity in animal models of Stargardt disease and durable expression and safety in non-human primates. SB-007 has been granted Orphan Drug Designation by the FDA in the US and the European Commission in Europe.

About SpliceBio
SpliceBio is a genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. The Company’s lead program, SB-007, targets the root cause of Stargardt disease, a genetic eye disease that causes blindness in children and adults. SpliceBio’s pipeline comprises additional gene therapy programs across therapeutic areas, including ophthalmology and neurology. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein, Protein Splicing, and protein engineering research. For additional information, please visit www.splice.bio.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Rivean Capital has acquired a majority stake in Acture Group from IK Partners

IK Partners

Rivean Capital (“Rivean”) is pleased to announce that it has signed a definitive agreement to acquire a majority stake in Acture Group (“Acture” or “the Group”), a leading provider of holistic employee welfare solutions, from IK Partners (“IK”). The stake is being acquired from the IK Small Cap II (“IK SC II”) Fund, with Co-Founder and current CEO Maudie Derks, as well as the management team, reinvesting alongside Rivean.

Founded in 2008 and headquartered in Nijmegen, the Netherlands, Acture is a specialised outsourced service provider supporting corporates and staffing agencies in managing employee absence. The Group has an integrated approach to employee welfare, offering complementary services such as absence management and reduction, including case management and reintegration programmes, combined with an absence insurance proposition.

Acture’s heritage and longstanding experience as a pioneer in the private social security services market in the Netherlands have resulted in large amounts of valuable data being translated into innovative case management solutions supported by proprietary technology. With IK’s support since 2020, the Group completed four add-on acquisitions in the Netherlands and three in Germany, to further complement its proposition and expand its geographical footprint. Acture is also currently rolling out a mental health absence management platform, Evermood, in the Netherlands and the DACH region. Through its full-service offering, Acture is well positioned to fully unburden customers who are confronted with labour market shortages and rising absenteeism costs. At present, the Group employs approximately 390 full-time employees across its offices in the Netherlands and Germany.

Ready for the next phase of growth

The Group’s ambition to reinforce its position as a leading European provider of specialised outsourced services and insurance products requires further investment in the organisation to help develop its digital offering and platform capabilities. With Rivean’s support, Acture will continue along its international growth trajectory, accelerating the execution of its strategic growth plan and transforming from a leading Dutch player in the social security market, to a European total employee welfare platform.

Maudie Derks, CEO of Acture, said: “With the recent add-on acquisitions, Acture has taken its first steps into the international arena while simultaneously expanding its offering with a tech-driven wellbeing proposition. Through the new partnership with Rivean, we plan to accelerate our international roll-out, advance our ambitious growth trajectory and further develop the total employee welfare management concept. We would like to thank IK for their support over the past few years and look forward to joining forces with Rivean.”

Nikolai Pronk, Managing Partner at Rivean Capital, commented: “We are very impressed by Acture’s leading market position, supporting its customers with an integrated offering and with a track record of consistent growth. We look forward to partnering with Maudie and the management team to support Acture in its next development and international growth phase.”

Sander van Vreumingen, Partner at IK and Advisor to the IK SC II Fund, added: “Over the past four years, we have had the pleasure of working very closely with Maudie and her team. From the start, we have been impressed with the combined professionalism and expertise of the team, which has enabled both the successful implementation of multiple organic growth initiatives and execution of several bolt-on acquisitions. We are proud of all that we have achieved in partnership with Acture and would like to wish Maudie and her team all the very best in the next stage of their journey.”

Completion of the transaction is subject to obtaining merger clearance, AFM and works council approval.

For further questions, please contact:

Rivean Capital
Maikel Wieland
Partner – Head of Investor Relations & Co-Investments
Phone: +41 43 268 20 30
m.wieland@riveancapital.com

IK Partners
Vidya Verlkumar
Head of Communications and Marketing
Phone: +44 7787 558 193
vidya.verlkumar@ikpartners.com

About Rivean Capital

Rivean Capital (“Rivean”) is a leading European private equity investor for mid-market transactions,
active in the DACH region, the Benelux countries, and Italy. Funds advised by Rivean Capital manage
over EUR 5 billion in assets. Since its inception in 1982, Rivean has supported more than 250
companies in realizing their growth ambitions and has a strong track record of supporting and scaling
successful high-tech businesses with cross-border growth agendas, including footprint expansions and
operational excellence trajectories. Headquartered in Amsterdam, Netherlands, Rivean Capital also has
offices in Brussels, Frankfurt/Main, Milan, and Zug, enabling a strong local presence across key
European markets. For more information, visit riveancapital.com

Read More

About IK Partners

IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH,
France, Nordics and the UK. Since 1989, IK has raised more than €17 billion of capital and invested in
over 195 European companies. IK supports companies with strong underlying potential, partnering with
management teams and investors to create robust, well-positioned businesses with excellent long-term
prospects. For more information, visit ikpartners.com

Categories: News

Tags:

Mayapada Healthcare Group Secures $157 Million Strategic Growth Investment from Bain Capital

BainCapital

Source: Mayapada Healthcare Group

Partnership Enables Mayapada Healthcare Group to Drive Innovation, Expand Reach, and Meet Indonesia’s Growing Healthcare Demand

Jakarta – December 12, 2024 – Mayapada Healthcare Group, a leading private premium healthcare provider specializing in multi-disciplinary and specialty care, announced a $157 million strategic growth investment from Bain Capital, a global private investment firm. It demonstrates strong confidence in Mayapada Hospital’s premium healthcare platform, which is well-positioned to meet the growing demand for high-quality care in Indonesia.

The investment be used to further scale access Mayapada Healthcare Group’s hospital platform through organic and strategic growth initiatives.  It will also support its mission to address Indonesia’s increasing demand for high-quality healthcare services, ultimately improving patient outcomes nationwide. This strategic partnership with Mayapada Healthcare Group aligns with Bain Capital’s global expertise in adding value to healthcare providers, including APMG, Estia Health, Grupo NotreDame Intermedica, HCA, and Nichii Gakken.

Founded in 2008, Mayapada Healthcare Group operates a growing network of premium hospitals to meet Indonesia’s increasing demand for high-quality healthcare. With seven hospitals across Indonesia, including a flagship hospital in Jakarta Selatan, the company serves a large part of the nation’s population and particularly in the densely populated island of Java. It prioritizes patient-centric care supported by advanced technology, specialized medical teams, and sustainable practices. Mayapada Healthcare Group has steadily expanded its footprint, adding five hospitals between 2018 and 2024, and currently has a substantial pipeline of brown and greenfield expansion. Committed to improving access to reliable healthcare, the organization continuously develops its facilities to address community needs, delivering safe, high-quality medical services to Indonesians.

“Indonesia faces a growing gap between healthcare supply and demand due to demographic shifts like an aging population and rising affluence,” said Jonathan Tahir, Chairman and Group CEO of Mayapada Healthcare Group. “Mayapada Healthcare Group is dedicated to making reliable, high-quality healthcare accessible to all Indonesians,” Tahir emphasized. “By leveraging technology and empowering our specialists, we aim to improve patient outcomes and set a new standard for innovative healthcare.”

“Bain Capital brings not just resources, but also deep expertise in helping healthcare providers thrive in a rapidly evolving ecosystem. We are excited for this partnership, which is rooted in a shared vision for what healthcare can achieve in Indonesia, ” Tahir concluded.

“Bain Capital is thrilled to partner with Mayapada Healthcare Group, whose mission and growth strategy align well with the evolving needs of Indonesia’s healthcare market,” said Sarit Chopra, Partner and Head of Special Situations, Asia at Bain Capital.  “As the private healthcare market in Indonesia is just beginning to develop, we have deep conviction that Mayapada has already built a strong foundation for continued growth. We’re committed to enhancing it with top talent, systems, and technology and we are eager to apply our global expertise to support Mayapada’s next growth phase.”

The investment was made through Bain Capital’s Special Situations strategy, which oversees over $20bn AUM and has invested $35bn since its inception.

The transaction is subject to regulatory and public shareholders approval, with targeted closing in early 2025.

###

About Bain Capital

Bain Capital, LP is one of the world’s leading private investment firms that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into numerous asset classes including private equity, credit, public equity, venture capital, real estate, life sciences, insurance, and other strategic areas of focus. The firm has offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management.  Bain Capital’s Special Situations strategy offers tailored capital solutions and strategic partnerships, meeting diverse needs across market cycles. With over $20 billion in assets under management, the team uniquely combines credit and equity expertise to deliver both financial and operational value beyond traditional providers. To learn more, visit (http://www.baincapital.com). Follow @BainCapital on LinkedIn and X (Twitter).

About Mayapada Healthcare Group
Mayapada Healthcare Group (PT Sejahteraraya Anugrahjaya Tbk.) (“SRAJ”) is a key business pillar of the Mayapada Group in the healthcare services sector. Mayapada Healthcare Group runs 7 (seven) hospitals with a total capacity of more than 1,000 beds, supported by more than 1,500 medical professionals who are experts in their fields. The seven hospitals of Mayapada Healthcare Group are Mayapada Hospital Tangerang, Mayapada Hospital Jakarta Selatan, Mayapada Hospital Bogor (BMC), Mayapada Hospital Kuningan, Mayapada Hospital Bandung and Mayapada Hospital Nusantara (IKN). Mayapada Hospital Jakarta Selatan obtained JCI accreditation in December 2024 while the other hospitals have the highest levels of accreditation domestically. Mayapada Healthcare Group operates several flagship services ‘Centers of Excellence’ including Tahir Neuroscience Center, Tahir Uronephrology Center, Cardiovascular Center, Gastrohepatology Center, Oncology Center, Orthopedic Center, Obstetrics & Gynecology Center, Pediatric Center, Internal Medicine and Pulmonology Center, Allergy-Immunology Center and the Autoimmune Center which is first and only service center in Indonesia. Mayapada Hospital Group has several projects in the pipeline and plans to operate more than 2,000 beds by 2027.

Media Contacts

 Asia / China

 Zhen Trudy Wang

Categories: News

Tags:

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

GIlde Healthcare
December 11, 2024
Basel (Switzerland)

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 million (approx. USD 147 million). With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

The new financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025. This includes additional development activities for basimglurant (NOE-101), an mGluR5 negative allosteric modulator currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC); gemlapodect (NOE-105), a PDE10a inhibitor in a Phase 2b trial for Tourette syndrome and under development for childhood-onset fluency disorder (COFD or stuttering); and NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and other symptoms of menopause.

Ilise Lombardo, MD, CEO of Noema Pharma, stated:”This latest financing underscores the strong support and confidence from investors in Noema’s vision to treat neuroscience-based conditions. We are thrilled to welcome EQT Life Sciences into this strong syndicate of investors and have Felice join our Board. EQT’s support and expertise alongside our syndicate of investors will be invaluable as we progress our clinical programs and strive to make a meaningful impact on patients’ lives.”

The Series B extension follows the initial Series B financing of CHF 103 million (USD 112 million) announced on March 2023, and a CHF 54 million (approx. USD 60 million) Series A round in December 2020.

About Noema Pharma
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises. Learn more at www.noemapharma.com.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million

EQT Life Science

Proceeds will be used to enable key late-stage clinical trial readouts for assets across several underserved neurological diseases with high unmet medical need.

EQT Life Sciences has led the extension, and joins a consortium of prominent global biotechnology investors.

The investment builds on EQT Life Sciences’ previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo, MD

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Noema Pharma (“the Company”). The clinical-stage biotech company headquartered in Basel, Switzerland is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series B extension brings the total capital raised in the round to CHF 130 million, including prior investments from Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

CNS disorders are a significant area of unmet medical need, affecting hundreds of millions of people worldwide who often face inadequate treatment options with limited effectiveness and significant side effects. Many of the conditions targeted by Noema Pharma have historically been difficult to treat due to their complex nature and the lack of effective therapies. By leveraging its diverse portfolio of neurological assets and innovative clinical pipeline, Noema Pharma is strongly positioned to address these debilitating disorders and provide much-needed hope and transformative solutions to patients living with these life-altering challenges. The Company’s portfolio includes four active Phase 2 trials, with key readouts from all studies anticipated in 2025.

Proceeds from the financing will drive the continued development of Noema Pharma’s clinical-stage assets, including its lead candidate basimglurant (NOE-101), a mGluR5 inhibitor currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC). Additionally, the Company is advancing gemlapodect (NOE-105), a PDE10a inhibitor in Phase 2 for Tourette syndrome and childhood onset fluency disorder (COFD or stuttering), as well as NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and additional symptoms of menopause.

Ilise Lombardo, MD, CEO of Noema Pharma, stated: “We are thrilled to welcome EQT Life Sciences as a lead investor and to have Felice join our Board. Their support and expertise will be invaluable as we progress our clinical programs and strive to make a meaningful impact on patients’ lives.”

Felice Verduyn-van Weegen, Partner at EQT who is joining the Company’s Board of Directors, commented: “Noema Pharma’s innovative approach to CNS disorders aligns very well with our investment strategy and we are excited to support their late-stage clinical pipeline and transformative therapies. Having worked with Ilise Lombardo on a previous successful investment, her exceptional leadership as a repeat entrepreneur further reinforces our confidence in Noema’s potential to deliver meaningful impact to patients in need.”

Contact
EQT Press Office, press@eqtpartners.com

Categories: News

Tags:

Angitia Biopharmaceuticals Announces $120 Million Series C Financing

BainCapital
Source: Angitia Biopharmaceuticals
  • Financing led by Bain Capital Life Sciences with significant participation from existing and new investors
  • Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline assets for the treatment of serious musculoskeletal diseases
  • Norbert Riedel, Ph.D., will join the Board of Directors

WOODLAND HILLS, Calif. December 11, 2024 – Angitia Biopharmaceuticals (“Angitia” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the closing of a $120 million Series C financing round. Bain Capital Life Sciences led the financing, with participation from new investor Janus Henderson and existing investors OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. Proceeds from the Series C will support Angitia’s robust pipeline of novel, differentiated treatments for serious musculoskeletal diseases.

“The broad support for Angitia in this financing validates the hard work of our team, the clinical progress of our programs, and the quality of our emerging data,” said Dr. David Ke, M.D., Chief Executive Officer of Angitia. “We express gratitude to our investors, new and returning, for their support in our journey to provide novel and effective treatments for patients with musculoskeletal disease, and we look forward to continuing to execute on developing these valuable medicines.”

Angitia is advancing AGA2118 and AGA2115, bispecific antibodies targeting sclerostin and DKK1, through clinical development for osteoporosis and osteogenesis imperfecta (OI), respectively. The two molecules represent the next generation of dual-acting treatments for skeletal disease, increasing bone formation and decreasing bone resorption. With these two bispecifics, Angitia seeks to promote stronger, more organized skeletal development in patients. The Company is also developing AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease.

In conjunction with the financing, Dr. Norbert Riedel, Ph.D., will join the Company’s Board of Directors. A seasoned scientist and biopharmaceutical executive, he brings decades of leadership experience to Angitia. Dr. Riedel serves on the board of directors of Jazz Pharmaceuticals and Eton Pharmaceuticals and is Chairman of the Board of Alcyone Therapeutics. He recently completed his tenure on the board of Cerevel Therapeutics. Dr. Riedel previously founded Aptinyx, Inc. and served as CEO of Naurex, which was acquired by Allergan in 2015. He also held senior roles at Baxter International and Hoechst-Marion Roussel (now Sanofi). Dr. Riedel holds a diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.

Angitia is enrolling patients in a Phase 2 study in postmenopausal women with AGA2118 (NCT06577935). AGA2115 is being developed for the treatment of OI and is currently in a first-in-human study (NCT06086613). AGA111 is being explored for use in patients undergoing lumbar interbody fusion in a Phase 3 study (NCT06115512).

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team’s extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.

Media Contacts

 Scott Lessne

Categories: News

Tags: